ACRS Stock: Aclaris Therapeutics reports positive topline data, surges 206%

ACRS Stock: Aclaris Therapeutics reports positive topline data, surges 206%
Aclaris Therapeutics (ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate…